全文获取类型
收费全文 | 3074篇 |
免费 | 191篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 31篇 |
儿科学 | 210篇 |
妇产科学 | 52篇 |
基础医学 | 302篇 |
口腔科学 | 64篇 |
临床医学 | 226篇 |
内科学 | 623篇 |
皮肤病学 | 132篇 |
神经病学 | 250篇 |
特种医学 | 37篇 |
外科学 | 435篇 |
综合类 | 39篇 |
一般理论 | 4篇 |
预防医学 | 138篇 |
眼科学 | 139篇 |
药学 | 333篇 |
中国医学 | 16篇 |
肿瘤学 | 242篇 |
出版年
2023年 | 12篇 |
2022年 | 45篇 |
2021年 | 100篇 |
2020年 | 62篇 |
2019年 | 87篇 |
2018年 | 121篇 |
2017年 | 87篇 |
2016年 | 100篇 |
2015年 | 89篇 |
2014年 | 144篇 |
2013年 | 170篇 |
2012年 | 242篇 |
2011年 | 231篇 |
2010年 | 169篇 |
2009年 | 114篇 |
2008年 | 218篇 |
2007年 | 184篇 |
2006年 | 165篇 |
2005年 | 172篇 |
2004年 | 186篇 |
2003年 | 128篇 |
2002年 | 110篇 |
2001年 | 39篇 |
2000年 | 31篇 |
1999年 | 25篇 |
1998年 | 41篇 |
1997年 | 25篇 |
1996年 | 24篇 |
1995年 | 20篇 |
1994年 | 13篇 |
1993年 | 7篇 |
1992年 | 10篇 |
1991年 | 22篇 |
1990年 | 7篇 |
1989年 | 11篇 |
1988年 | 5篇 |
1987年 | 6篇 |
1986年 | 4篇 |
1984年 | 3篇 |
1983年 | 6篇 |
1982年 | 4篇 |
1981年 | 6篇 |
1980年 | 7篇 |
1979年 | 3篇 |
1978年 | 3篇 |
1977年 | 4篇 |
1974年 | 2篇 |
1973年 | 2篇 |
1968年 | 2篇 |
1966年 | 2篇 |
排序方式: 共有3273条查询结果,搜索用时 31 毫秒
11.
Subodh Varshney Sandesh Sharma Viniyendra Pamecha Ajit Sewkani Lalish Jhawar Vinod Narkhede Virendra Tewari Kailash Patel 《Indian journal of gastroenterology》2003,22(3):91-93
INTRODUCTION: Radiofrequency (RF) tissue ablation has been tried safely and effectively in the West as percutaneous local tissue ablation therapy. We present our experience with this technique in malignant lesions. METHODS: RF tumor ablation was done using an RF generator (Berchtold; Germany) generating 35-50 RF watts of power output. The RF needle was placed in the tumor under image guidance (n = 22) or at open surgery (n = 1). Around 1500 watts/cm3 RF energy was delivered to the tumor. Over 21 months, 23 patients underwent the procedure for 73 lesions, including metastatic liver lesions (n = 21) and locally advanced inoperable carcinoma of pancreas (n = 2). RESULTS: All lesions less than 3 cm in size (n = 15) and 39% of lesions 3-4 cm in size (17/44) had complete necrosis. Residual tumor was seen in 27/44 lesions (61%) 3-4 cm in size and in all 14 lesions more than 4 cm in size. There was no mortality or major morbidity. There were two minor complications (ascites 1, pleural effusion 1). Of 21 patients treated for liver metastases, 10 are still alive (6-month survival 19/21 [90%] and 12-month survival 11/17 [64.7%]). Only 2 of 32 (6.2%) lesions with complete necrosis had local recurrence. CONCLUSION: RF tumor ablation is a safe and effective local tissue ablative method in Indian patients. 相似文献
12.
A 32-year-old male presented with progressive weakness and numbness of both upper limbs of one-month duration. The patient had weakness and wasting of small muscles of both hands with weak grip. Sensory system revealed graded sensory loss to pain, temperature and touch in C5 to T1 distribution and vibration and joint position sense from C5 to C8 in the both upper limbs. There was areflexia in the upper limbs while there was no motor or sensory deficit in the lower limbs. The cortical potential on stimulation of posterior tibial nerve was prolonged on both sides. On MR imaging of the cervical spine there was iso to low intense lesion which was hyperintense on T2-weighted imaging along the dorsal aspect of the cord extending from C2 to C6 level. The axial images showed involvement of the posterior column. The serum vitamin B12 level was found to be low. The patient responded to parenteral cyanocobalamine therapy and the radiological lesion subsequently resolved. 相似文献
13.
14.
15.
Pharmaceutical Research - 相似文献
16.
17.
Van Buskirk Glenn A. González Mario A. Shah Vinod P. Barnhardt Scott Barrett Colin Berge Stephen Cleary Gary Chan Keith Flynn Gordon Foster Thomas Gale Robert Garrison Raymond Gochnour Scott Gotto Amanda Govil Sharad Gray Vivian A. Hammar James Harder Samuel Hoiberg Charles Hussain Ajaz Karp Carol Llanos Hector Mantelle Juan Noonan Patrick Swanson David Zerbe Horst 《Pharmaceutical research》1997,14(7):848-852
Pharmaceutical Research - 相似文献
18.
Recruitment of complement factor H-like protein 1 promotes intracellular invasion by group A streptococci 总被引:9,自引:0,他引:9
下载免费PDF全文
![点击此处可从《Infection and immunity》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Numerous microbial pathogens exploit complement regulatory proteins such as factor H (FH) and factor H-like protein 1 (FHL-1) for immune evasion. Fba is an FHL-1 and FH binding protein expressed on the surface of the human pathogenic bacterium, Streptococcus pyogenes, a common agent of pharyngeal, skin, and soft-tissue infections. In the present study, we demonstrate that Fba and FHL-1 work in concert to promote invasion of epithelial cells by S. pyogenes. Fba fragments were expressed as recombinant proteins and assayed for binding of FHL-1 and FH by Western blotting, enzyme-linked immunosorbent assay, and surface plasmon resonance. A binding site for FHL-1 and FH was localized to the N-terminal half of Fba, a region predicted to contain a coiled-coil domain. Deletion of this coiled-coil domain greatly reduced FHL-1 and FH binding. PepSpot analyses identified a 16-amino-acid segment of Fba which overlaps the coiled-coil domain that binds both FHL-1 and FH. To localize the Fba binding site in FHL-1 and FH, surface plasmon resonance was used to assess the interactions between the streptococcal protein and a series of recombinant FH deletion constructs. The Fba binding site was localized to short consensus repeat 7 (SCR 7), a domain common to FHL-1 and FH. SCR 7 contains a heparin binding site, and heparin was found to inhibit FHL-1 binding to Fba. FHL-1 promoted entry of Fba(+) group A streptococci into epithelial cells in a dose-dependent manner but did not affect invasion by an isogenic fba mutant. To our knowledge, this is the first report of a bacterial pathogen exploiting a soluble complement regulatory protein for entry into host cells. 相似文献
19.
Vinod Chandran 《Expert Review of Clinical Immunology》2020,16(5):471-478
ABSTRACT
Introduction
Biomarkers may help influence long-term outcomes of psoriatic disease by improving the objective assessment of the presence and severity of psoriatic arthritis (PsA) and by guiding treatment selection. However, there are no validated biomarkers for PsA. 相似文献20.